ABUS - Latest News

Arbutus Biopharma Corp (ABUS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $922.5M. Trailing twelve-month P/E ratio is 6.03. Beta to the broader market is 0.60.

The article list below shows the most recent ABUS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ABUS Headlines

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

globenewswire.com - Aug 12, 2026

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.

GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue

businesswire.com - Aug 3, 2026

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the launch of Invenia™ ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue™, a redesig

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

globenewswire.com - Jul 16, 2026

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanopart

Arbutus Biopharma: Moderna Validates My IP Bull Case

seekingalpha.com - Jul 13, 2026

Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusira

How News Affects ABUS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ABUS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ABUS news questions

What is the latest ABUS news headline?

The most recent ABUS headline (Aug 12, 2026) is "Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ABUS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ABUS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ABUS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.